SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Bay Area tech sector soared for three years in the wake of a global pandemic, but the industry’s jobs boom has since nosedived into a ...

The Indian QR coding programme meant to protect domestic drug supplies has failed, and is now a gift to the counterfeiters.

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a ...

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

On March 4, 2025, filings revealed that CEO Stephane Bancel purchased 160,314 shares of MRNA stock between $31.04 and $31.53, ...